Literature DB >> 1918978

IFN-gamma enhances sensitivity of human macrophages to extracellular ATP-mediated lysis.

D K Blanchard1, S McMillen, J Y Djeu.   

Abstract

In an effort to determine the mechanism by which autologous monocytes are killed by lymphokine-activated killer cells, soluble mediators were examined for their direct effect on target cells. Extracellular ATP (ATPo), but not ADP, was found to lyse human culture-derived macrophages in a 6-h 51Cr-release assay. Treatment of monocytes with human rIFN-gamma rendered those cells significantly more sensitive to ATPo compared to untreated or granulocyte-macrophage CSF-(GM-CSF) treated cells. In addition, IFN-gamma-treated macrophages released approximately 80% of 51Cr label within 15 min after the addition of ATPo, whereas GM-CSF-treated cells did not release significant levels of radiolabel until 4 to 6 h after initial stimulation with ATPo. Time course studies also demonstrated that 3 days of incubation of macrophages with IFN-gamma induced optimal sensitivity to ATPo, although some effect was noted after 4 h of incubation. Thus, IFN-gamma treatment of macrophages elicited increased sensitivity to ATPo-mediated lysis, a phenomenon characterized by rapid release of 51Cr from labeled cells and which is possibly due to induction or activation of surface ATP-binding receptors different from those present on GM-CSF-treated or untreated macrophages.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1918978

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Two different ionotropic receptors are activated by ATP in rat microglia.

Authors:  S Visentin; M Renzi; C Frank; A Greco; G Levi
Journal:  J Physiol       Date:  1999-09-15       Impact factor: 5.182

Review 2.  P2 receptor subtypes in the cardiovascular system.

Authors:  S P Kunapuli; J L Daniel
Journal:  Biochem J       Date:  1998-12-15       Impact factor: 3.857

3.  Characterization of the cytotoxic effect of extracellular ATP in J774 mouse macrophages.

Authors:  M Murgia; P Pizzo; T H Steinberg; F Di Virgilio
Journal:  Biochem J       Date:  1992-12-15       Impact factor: 3.857

4.  A comparative study of interleukin-1beta production and p2x7 expression after ATP stimulation by peripheral blood mononuclear cells isolated from rheumatoid arthritis patients and normal healthy controls.

Authors:  Ahmed Al-Shukaili; Juma Al-Kaabi; Batool Hassan
Journal:  Inflammation       Date:  2007-11-27       Impact factor: 4.092

5.  The purinergic P2Z receptor of human macrophage cells. Characterization and possible physiological role.

Authors:  S Falzoni; M Munerati; D Ferrari; S Spisani; S Moretti; F Di Virgilio
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

6.  Spontaneous cell fusion in macrophage cultures expressing high levels of the P2Z/P2X7 receptor.

Authors:  P Chiozzi; J M Sanz; D Ferrari; S Falzoni; A Aleotti; G N Buell; G Collo; F Di Virgilio
Journal:  J Cell Biol       Date:  1997-08-11       Impact factor: 10.539

7.  Purinergic modulation of interleukin-1 beta release from microglial cells stimulated with bacterial endotoxin.

Authors:  D Ferrari; P Chiozzi; S Falzoni; S Hanau; F Di Virgilio
Journal:  J Exp Med       Date:  1997-02-03       Impact factor: 14.307

Review 8.  New insights of P2X7 receptor signaling pathway in alveolar functions.

Authors:  Amarjit Mishra
Journal:  J Biomed Sci       Date:  2013-05-01       Impact factor: 8.410

9.  Apoptosis, but not necrosis, of infected monocytes is coupled with killing of intracellular bacillus Calmette-Guérin.

Authors:  A Molloy; P Laochumroonvorapong; G Kaplan
Journal:  J Exp Med       Date:  1994-10-01       Impact factor: 14.307

10.  A novel ligand in lymphocyte-mediated cytotoxicity: expression of the beta subunit of H+ transporting ATP synthase on the surface of tumor cell lines.

Authors:  B Das; M O Mondragon; M Sadeghian; V B Hatcher; A J Norin
Journal:  J Exp Med       Date:  1994-07-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.